Breckenridge Pharmaceutical Initiates Class II Recall of Duloxetine Due to N-Nitroso Impurity
Breckenridge Pharmaceutical, Inc. has initiated a Class II recall of 14,749 bottles of Duloxetine Delayed-Release Capsules, USP, 30mg, due to N-nitroso-duloxetine impurity exceeding FDA limits. This event, stemming from CGMP deviations at manufacturer Towa Pharmaceutical Europe, S.L., necessitates immediate supply chain reassessment for procurement and regulatory teams, highlighting critical quality control vulnerabilities.
FDA Findings: Impurity-Driven Recall of Duloxetine Signals CGMP Failures
Breckenridge Pharmaceutical, Inc., based in Berkeley Heights, NJ, has initiated a Class II voluntary recall, identified as D-0270-2025, for specific lots of Duloxetine Delayed-Release Capsules, USP, 30mg. This critical action, initiated on February 28, 2025, stems from Current Good Manufacturing Practice (CGMP) deviations, specifically the presence of N-nitroso-duloxetine impurity at levels exceeding the FDA's recommended interim limits. The affected product, distributed nationwide, includes 14,749 bottles from Lot#: 240225C, with an expiration date of January 2027. This impurity, a nitrosamine, is a significant concern for regulatory bodies globally due to its potential genotoxic properties, placing a heightened burden on manufacturers and distributors to ensure product safety. For procurement directors and regulatory affairs heads, this recall underscores the severe commercial and patient safety risks associated with CGMP non-compliance. The presence of an N-nitroso impurity above FDA thresholds means that the product is considered adulterated, necessitating its removal from the market. This directly impacts supply continuity for a widely used antidepressant and neuropathic pain medication, requiring immediate action to identify alternative sources and prevent stockouts. Furthermore, it signals that the FDA is actively monitoring and enforcing limits on these impurities, demanding rigorous quality control and analytical testing from all stakeholders in the pharmaceutical supply chain.
Dual Entity Exposure: Breckenridge and Towa's Roles in the Duloxetine Supply Chain
The recall involves two key entities: Breckenridge Pharmaceutical, Inc., which distributes the product from its Berkeley Heights, NJ, facility, and Towa Pharmaceutical Europe, S.L., the manufacturer located in Martorelles, Barcelona, Spain. This dual-entity structure highlights the complex interdependencies within the global pharmaceutical supply chain and the shared responsibility for product quality and regulatory compliance. Breckenridge Pharmaceutical, as the distributor, is responsible for the recalled product under NDC 51991-747-10, among others (51991-746, 51991-748, 51991-750), and holds the Abbreviated New Drug Application (ANDA203088) for Duloxetine Hydrochloride. For supply chain VPs and business development executives, this situation emphasizes the critical need for robust quality agreements and diligent oversight of contract manufacturing organizations (CMOs) and third-party distributors. While Breckenridge initiated the recall, the root cause points to manufacturing deficiencies at Towa Pharmaceutical Europe, S.L. Companies sourcing APIs or finished products from either entity must now re-evaluate their supplier qualification processes, conduct thorough audits, and ensure that quality management systems are in place to detect and prevent such impurities. The geographical separation between the distributor in the United States and the manufacturer in Spain also complicates remediation efforts and regulatory oversight, potentially extending resolution timelines and increasing compliance costs.
Market Impact and Supply Chain Vulnerability for Duloxetine Hydrochloride
The nationwide distribution of Breckenridge Pharmaceutical's Duloxetine Delayed-Release Capsules, USP, 30mg, means that healthcare providers and patients across the United States are directly impacted by this Class II recall. With 14,749 bottles of the 30mg strength affected, procurement teams must immediately assess their current inventory levels and the potential for supply disruptions. Duloxetine Hydrochloride, a widely prescribed generic, is crucial for treating major depressive disorder, generalized anxiety disorder, diabetic peripheral neuropathic pain, fibromyalgia, and chronic musculoskeletal pain. Any significant disruption can lead to patient treatment interruptions and increased healthcare system burden. For business development executives and procurement directors, this event signals a critical vulnerability in the supply chain for generic Duloxetine. While other manufacturers supply Duloxetine, the sudden removal of a substantial quantity from the market can strain existing alternatives, potentially leading to price volatility or temporary shortages. Companies relying on Breckenridge Pharmaceutical as a supplier for Duloxetine or other products should initiate contingency planning, including identifying and qualifying secondary or tertiary suppliers. This incident underscores the importance of a diversified supplier base and proactive risk management strategies to mitigate the commercial impact of such recalls, ensuring continuity of patient care and market presence.
Proactive Risk Mitigation: Addressing Unidentified Alternatives and Regulatory History Gaps
In the immediate aftermath of this recall, a critical challenge for procurement and regulatory teams is the absence of readily identified alternative suppliers for Duloxetine Hydrochloride within the available intelligence. This lack of explicit alternative sourcing options means that companies must undertake their own comprehensive due diligence to identify and qualify new suppliers, a process that can be time-consuming and resource-intensive. Without pre-vetted alternatives, organizations face heightened exposure to supply chain disruptions and potential market share loss if they cannot quickly secure compliant product. Furthermore, the available intelligence does not detail a prior regulatory history for Breckenridge Pharmaceutical, Inc. or Towa Pharmaceutical Europe, S.L. regarding similar CGMP deviations or nitrosamine impurities. While this might suggest an isolated incident, it does not diminish the severity of the current recall. For regulatory affairs heads, this emphasizes the need for continuous monitoring of supplier quality systems, even in the absence of a documented history of non-compliance. Proactive measures, such as enhanced supplier audits, robust quality agreements with clear impurity specifications, and independent analytical testing, are paramount to mitigate risks from unforeseen quality issues and ensure long-term supply chain resilience.
Ongoing Regulatory Scrutiny and Remediation Pathways for Breckenridge and Towa
The FDA has classified this recall as "Ongoing," indicating that the agency's oversight and the firm's corrective actions are still in progress. Although firm-initiated and voluntary, a Class II recall due to CGMP deviations and impurity exceedances typically triggers intense regulatory scrutiny. The FDA will expect Breckenridge Pharmaceutical, Inc. and Towa Pharmaceutical Europe, S.L. to conduct a thorough investigation into the root cause of the N-nitroso-duloxetine impurity, implement comprehensive corrective and preventive actions (CAPA), and demonstrate sustained compliance with CGMP regulations. This could involve facility inspections by the FDA, particularly at the manufacturing site in Spain, to verify the effectiveness of the CAPA plan. For business development and regulatory affairs executives, the "Ongoing" status implies that the commercial implications extend beyond the immediate product withdrawal. Future market access for Breckenridge's Duloxetine, and potentially other products manufactured by Towa, could be jeopardized if the remediation efforts are deemed insufficient by the FDA. Companies sourcing from either entity should anticipate potential delays in product approvals, increased regulatory burdens, and a need for enhanced due diligence. A successful resolution will require transparent communication with the FDA, robust quality system improvements, and a clear demonstration of control over impurity profiles to restore regulatory confidence and ensure continued market viability.